Phase I, multiple ascending dose trial of XP 23829 and dimethyl fumarate in volunteers.
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2014
At a glance
- Drugs XP 23829 (Primary) ; Dimethyl fumarate
- Indications Multiple sclerosis; Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- 28 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 08 Nov 2013 Additional results were published in a XenoPort media release.
- 09 Sep 2013 Status changed from recruiting to completed.